Adjuvant Endocrine Therapy in Premenopausal Patients With Hormone Receptor-Positive Early Breast Cancer: Evidence Evaluation and GRADE Recommendations by the Italian Association of Medical Oncology (AIOM)

This is a clinical practice guideline for premenopausal patients with hormone receptor-positive early breast cancer. The guideline examines adjuvant ovarian function suppression (OFS) during the treatment of these patients. The addition of OFS to tamoxifen therapy is discussed for low-risk and high-risk patients, as well as the use of aromatase inhibitors instead of tamoxifen in high-risk patients.